Literature DB >> 26699943

Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension.

Lydie Plecitá-Hlavatá1, Jan Tauber1, Min Li2, Hui Zhang2,3, Amanda R Flockton2, Soni Savai Pullamsetti4, Prakash Chelladurai4, Angelo D'Alessandro5, Karim C El Kasmi6, Petr Ježek1, Kurt R Stenmark2.   

Abstract

Remodeling of the distal pulmonary artery wall is a characteristic feature of pulmonary hypertension (PH). In hypoxic PH, the most substantial pathologic changes occur in the adventitia. Here, there is marked fibroblast proliferation and profound macrophage accumulation. These PH fibroblasts (PH-Fibs) maintain a hyperproliferative, apoptotic-resistant, and proinflammatory phenotype in ex vivo culture. Considering that a similar phenotype is observed in cancer cells, where it has been associated, at least in part, with specific alterations in mitochondrial metabolism, we sought to define the state of mitochondrial metabolism in PH-Fibs. In PH-Fibs, pyruvate dehydrogenase was markedly inhibited, resulting in metabolism of pyruvate to lactate, thus consistent with a Warburg-like phenotype. In addition, mitochondrial bioenergetics were suppressed and mitochondrial fragmentation was increased in PH-Fibs. Most importantly, complex I activity was substantially decreased, which was associated with down-regulation of the accessory subunit nicotinamide adenine dinucleotide reduced dehydrogenase (ubiquinone) Fe-S protein 4 (NDUFS4). Owing to less-efficient ATP synthesis, mitochondria were hyperpolarized and mitochondrial superoxide production was increased. This pro-oxidative status was further augmented by simultaneous induction of cytosolic nicotinamide adenine dinucleotide phosphate reduced oxidase 4. Although acute and chronic exposure to hypoxia of adventitial fibroblasts from healthy control vessels induced increased glycolysis, it did not induce complex I deficiency as observed in PH-Fibs. This suggests that hypoxia alone is insufficient to induce NDUFS4 down-regulation and constitutive abnormalities in complex I. In conclusion, our study provides evidence that, in the pathogenesis of vascular remodeling in PH, alterations in fibroblast mitochondrial metabolism drive distinct changes in cellular behavior, which potentially occur independently of hypoxia.

Entities:  

Keywords:  adventitial fibroblasts; complex I; mitochondria; oxidative metabolism; pulmonary hypertension

Mesh:

Substances:

Year:  2016        PMID: 26699943      PMCID: PMC4942204          DOI: 10.1165/rcmb.2015-0142OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  48 in total

Review 1.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing.

Authors:  Robert D Guzy; Beatrice Hoyos; Emmanuel Robin; Hong Chen; Liping Liu; Kyle D Mansfield; M Celeste Simon; Ulrich Hammerling; Paul T Schumacker
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

Review 3.  Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect.

Authors:  Katherine A Cottrill; Stephen Y Chan
Journal:  Eur J Clin Invest       Date:  2013-04-26       Impact factor: 4.686

4.  Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia.

Authors:  Mita Das; Nana Burns; Shelly J Wilson; Wojciech M Zawada; Kurt R Stenmark
Journal:  Cardiovasc Res       Date:  2008-01-24       Impact factor: 10.787

5.  Gene transfer of extracellular superoxide dismutase ameliorates pulmonary hypertension in rats.

Authors:  Fumihiko Kamezaki; Hiromi Tasaki; Kazuhito Yamashita; Masato Tsutsui; Shinichiro Koide; Sei Nakata; Akihide Tanimoto; Masahiro Okazaki; Yasuyuki Sasaguri; Tetsuo Adachi; Yutaka Otsuji
Journal:  Am J Respir Crit Care Med       Date:  2007-10-25       Impact factor: 21.405

Review 6.  Fibroblasts as novel therapeutic targets in chronic inflammation.

Authors:  S J Flavell; T Z Hou; S Lax; A D Filer; M Salmon; C D Buckley
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

7.  The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver.

Authors:  D H Williamson; P Lund; H A Krebs
Journal:  Biochem J       Date:  1967-05       Impact factor: 3.857

Review 8.  Mitochondria: from cell death executioners to regulators of cell differentiation.

Authors:  Atsuko Kasahara; Luca Scorrano
Journal:  Trends Cell Biol       Date:  2014-09-02       Impact factor: 20.808

9.  The role of non-hematopoietic stromal cells in the persistence of inflammation.

Authors:  Francesca Barone; Saba Nayar; Chris D Buckley
Journal:  Front Immunol       Date:  2013-01-14       Impact factor: 7.561

10.  Suppression of mitochondrial complex I influences cell metastatic properties.

Authors:  Xuelian He; Aifen Zhou; Hao Lu; Yong Chen; Guochang Huang; Xin Yue; Peiwei Zhao; Yanxiang Wu
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more
  32 in total

1.  Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.

Authors:  Lian Tian; Monica Neuber-Hess; Jeffrey Mewburn; Asish Dasgupta; Kimberly Dunham-Snary; Danchen Wu; Kuang-Hueih Chen; Zhigang Hong; Willard W Sharp; Shelby Kutty; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2017-03-06       Impact factor: 4.599

Review 2.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Identification of Infants at Risk for Chronic Lung Disease at Birth. Potential for a Personalized Approach to Disease Prevention.

Authors:  Angelo D'Alessandro; Eva Nozik-Grayck; Kurt R Stenmark
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

4.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

5.  Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension.

Authors:  Anna R Hemnes; Min Zhao; James West; John H Newman; Stuart Rich; Stephen L Archer; Ivan M Robbins; Timothy S Blackwell; Joy Cogan; James E Loyd; Zhongming Zhao; Christa Gaskill; Christopher Jetter; Jonathan A Kropski; Susan M Majka; Eric D Austin
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

Review 6.  Mitochondrial Uncoupling Proteins: Subtle Regulators of Cellular Redox Signaling.

Authors:  Petr Ježek; Blanka Holendová; Keith D Garlid; Martin Jabůrek
Journal:  Antioxid Redox Signal       Date:  2018-03-14       Impact factor: 8.401

Review 7.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

8.  Hypertonic Saline Primes Activation of the p53-p21 Signaling Axis in Human Small Airway Epithelial Cells That Prevents Inflammation Induced by Pro-inflammatory Cytokines.

Authors:  Fabia Gamboni; Cameron Anderson; Sanchayita Mitra; Julie A Reisz; Travis Nemkov; Monika Dzieciatkowska; Kenneth L Jones; Kirk C Hansen; Angelo D'Alessandro; Anirban Banerjee
Journal:  J Proteome Res       Date:  2016-08-29       Impact factor: 4.466

Review 9.  Cellular Metabolism in Lung Health and Disease.

Authors:  Gang Liu; Ross Summer
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

10.  Metabolic Reprogramming Regulates the Proliferative and Inflammatory Phenotype of Adventitial Fibroblasts in Pulmonary Hypertension Through the Transcriptional Corepressor C-Terminal Binding Protein-1.

Authors:  Min Li; Suzette Riddle; Hui Zhang; Angelo D'Alessandro; Amanda Flockton; Natalie J Serkova; Kirk C Hansen; Radu Moldovan; B Alexandre McKeon; Maria Frid; Sushil Kumar; Hong Li; Hongbing Liu; Angela Caánovas; Juan F Medrano; Milton G Thomas; Dijana Iloska; Lydie Plecitá-Hlavatá; Petr Ježek; Soni Pullamsetti; Mehdi A Fini; Karim C El Kasmi; QingHong Zhang; Kurt R Stenmark
Journal:  Circulation       Date:  2016-08-25       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.